Opinion|Videos|July 29, 2024
Decision-Making in CLL: The Role of Real-World Evidence
A discussion on therapeutic decision-making in CLL and the role of real-world evidence.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- How do you integrate real-world evidence into your clinical decision-making process for BTK inhibitors in CLL?
Advertisement
Related to this article
This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Aligning financial incentives with patient-centered care is becoming an increasingly complex path to navigate within oncology.
Advertisement
Advertisement
Trending on AJMC
1
Pharmacists Bridge the Vaccine Trust Gap as COVID-19 Persists
2
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
3
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
4
Who Recommends COVID-19 Vaccines Without ACIP?
5